Clinical development of gene therapy: results and lessons from recent successes

Molecular Therapy Methods and Clinical Development

Volumn 3, Issue , 2016, Pages 16034-

  Kumar, Sandeep RP ^a   Markusic, David M ^a   Biswas, Moanaro ^a   High, Katherine A ^b   Herzog, Roland W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Ophthalmology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; GENE THERAPY AGENT; T LYMPHOCYTE RECEPTOR; HEMOGLOBIN;

BETA THALASSEMIA; CANCER IMMUNOTHERAPY; FAMILIAL DISEASE; GENE EDITING; GENE THERAPY; HEMOPHILIA B; HUMAN; IMMUNE DEFICIENCY; MALIGNANT NEOPLASM; MULTICENTER STUDY (TOPIC); NEUROLOGIC DISEASE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETINA DISEASE; REVIEW; SICKLE CELL ANEMIA; BLOOD CLOTTING DISORDER; CANCER GENE THERAPY; CLINICAL TRIAL (TOPIC); GENE VECTOR; GENETIC DISORDER;

EID: 85015160162     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2016.34     Document Type: Review

References (142)

1. 1 Naldini, L, Medicine. A comeback for gene therapy. Science 326 (2009), 805–806.
2. 2 Herzog, RW, Cao, O, Srivastava, A, Two decades of clinical gene therapy–success is finally mounting. Discov Med 9 (2010), 105–111.
3. 3 Couzin-Frankel, J, Breakthrough of the year 2013. Cancer immunotherapy. Science 342 (2013), 1432–1433.
4. 4 Wang, X, Shin, SC, Chiang, AF, Khan, I, Pan, D, Rawlings, DJ, et al. Intraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A. Mol Ther 23 (2015), 617–626.
5. 5 Brown, BD, A shot in the bone corrects a genetic disease. Mol Ther 23 (2015), 614–615.
6. 6 Ylä-Herttuala, S, Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther 20 (2012), 1831–1832.
7. 7 Kaufman, HL, Kohlhapp, FJ, Zloza, A, Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 14 (2015), 642–662.
8. 8 Griffith, LM, Cowan, MJ, Notarangelo, LD, Kohn, DB, Puck, JM, Pai, SY, et al., workshop participants, Primary Immune Deficiency Treatment Consortium (PIDTC) report. J Allergy Clin Immunol 133 (2014), 335–347.
9. 9 Cavazzana-Calvo, M, Payen, E, Negre, O, Wang, G, Hehir, K, Fusil, F, et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467 (2010), 318–322.
10. 10 Aiuti, A, Biasco, L, Scaramuzza, S, Ferrua, F, Cicalese, MP, Baricordi, C, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science, 341, 2013, 1233151.
11. 11 Aiuti, A, Cattaneo, F, Galimberti, S, Benninghoff, U, Cassani, B, Callegaro, L, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 360 (2009), 447–458.
12. 12 Aiuti, A, Slavin, S, Aker, M, Ficara, F, Deola, S, Mortellaro, A, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296 (2002), 2410–2413.
13. 13 Biffi, A, Montini, E, Lorioli, L, Cesani, M, Fumagalli, F, Plati, T, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science, 341, 2013, 1233158.
14. 14 Gaspar, HB, Cooray, S, Gilmour, KC, Parsley, KL, Zhang, F, Adams, S, et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med, 3, 2011, 97ra80.
15. 15 Hacein-Bey-Abina, S, Garrigue, A, Wang, GP, Soulier, J, Lim, A, Morillon, E, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118 (2008), 3132–3142.
16. 16 Hacein-Bey-Abina, S, von Kalle, C, Schmidt, M, Le Deist, F, Wulffraat, N, McIntyre, E, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348 (2003), 255–256.
17. 17 Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, Leboulch, P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 (2003), 415–419.
18. 18 Howe, SJ, Mansour, MR, Schwarzwaelder, K, Bartholomae, C, Hubank, M, Kempski, H, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118 (2008), 3143–3150.
19. 19 Montini, E, Cesana, D, Schmidt, M, Sanvito, F, Ponzoni, M, Bartholomae, C, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24 (2006), 687–696.
20. 20 Modlich, U, Navarro, S, Zychlinski, D, Maetzig, T, Knoess, S, Brugman, MH, et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 17 (2009), 1919–1928.
21. 21 Xu, W, Russ, JL, Eiden, MV, Evaluation of residual promoter activity in γ-retroviral self-inactivating (SIN) vectors. Mol Ther 20 (2012), 84–90.
22. 22 Hacein-Bey-Abina, S, Pai, SY, Gaspar, HB, Armant, M, Berry, CC, Blanche, S, et al. A modified γ-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med 371 (2014), 1407–1417.
23. 23 Touzot, F, Moshous, D, Creidy, R, Neven, B, Frange, P, Cros, G, et al. Faster T-cell development following gene therapy compared with haploidentical HSCT in the treatment of SCID-X1. Blood 125 (2015), 3563–3569.
24. 24 Candotti, F, Shaw, KL, Muul, L, Carbonaro, D, Sokolic, R, Choi, C, et al. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood 120 (2012), 3635–3646.
25. 25 Kohn, DB, Hershfield, MS, Carbonaro, D, Shigeoka, A, Brooks, J, Smogorzewska, EM, et al. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat Med 4 (1998), 775–780.
26. 26 Kohn, DB, Weinberg, KI, Nolta, JA, Heiss, LN, Lenarsky, C, Crooks, GM, et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med 1 (1995), 1017–1023.
27. 27 Aiuti, A, Cassani, B, Andolfi, G, Mirolo, M, Biasco, L, Recchia, A, et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest 117 (2007), 2233–2240.
28. 28 Gaspar, HB, Gene therapy for ADA-SCID: defining the factors for successful outcome. Blood 120 (2012), 3628–3629.
29. 29 Otsu, M, Yamada, M, Nakajima, S, Kida, M, Maeyama, Y, Hatano, N, et al. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning. J Clin Immunol 35 (2015), 384–398.
30. 30 Gaspar, BB, Rivat, C, Himoudi, N, Gilmour, K, Booth, C, Xu-Bayford, J, Immunological and metabolic correction after lentiviral vector mediated haematopoietic stem cell gene therapy for ADA deficiency. J Clin Immunol 34:Suppl 2 (2014), S167–S168.
31. 31 Cicalese, MP, Aiuti, A, Clinical applications of gene therapy for primary immunodeficiencies. Hum Gene Ther 26 (2015), 210–219.
32. 32 Boztug, K, Schmidt, M, Schwarzer, A, Banerjee, PP, Díez, IA, Dewey, RA, et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 363 (2010), 1918–1927.
33. 33 Braun, CJ, Boztug, K, Paruzynski, A, Witzel, M, Schwarzer, A, Rothe, M, et al. Gene therapy for Wiskott-Aldrich syndrome–long-term efficacy and genotoxicity. Sci Transl Med, 6, 2014, 227ra33.
34. 34 Qasim, W, Gennery, AR, Gene therapy for primary immunodeficiencies: current status and future prospects. Drugs 74 (2014), 963–969.
35. 35 Ferrua, FM, Galimberti, S, Scaramuzza, S, Giannelli, S, Pajno, R, Dionisio, F, et al. Safety and clinical benefit of lentiviral hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Blood, 126, 2015, 259.
36. 36 Chu, JI, Myriam Armant, L, Male, F, Dansereau, CH, MacKinnon, B, Burke, CJ, et al. Gene therapy using a self-inactivating lentiviral vector improves clinical and laboratory manifestations of Wiskott-Aldrich syndrome. Blood, 126, 2015, 260.
37. 37 Grez, M, Reichenbach, J, Schwäble, J, Seger, R, Dinauer, MC, Thrasher, AJ, Gene therapy of chronic granulomatous disease: the engraftment dilemma. Mol Ther 19 (2011), 28–35.
38. 38 Stein, S, Ott, MG, Schultze-Strasser, S, Jauch, A, Burwinkel, B, Kinner, A, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 16 (2010), 198–204.
39. 39 Walters, MC, Suradej Hongeng, J, Kwiatkowski, J, Schiller, GJ, Kletzel, M, Ho, PJ, et al. Update of results from the Northstar Study (HGB-204): a phase 1/2 study of gene therapy for beta-thalassemia major via transplantation of autologous hematopoietic stem cells transduced ex-vivo with a lentiviral beta AT87Q-globin vector (LentiGlobin BB305 Drug Product). Blood, 126, 2015, 201.
40. 40 Cavazzana, M, Emmanuel Payen, J-A, Suarez, F, Beuzard, Y, Touzot, F, Cavallesco, R, et al. Outcomes of gene therapy for severe sickle disease and beta-thalassemia major via transplantation of autologous hematopoietic stem cells transduced ex vivo with a lentiviral beta AT87Q-globin vector. Blood, 126, 2015, 202.
41. 41 Malik, P, Gene therapy for hemoglobinopathies: tremendous successes and remaining caveats. Mol Ther 24 (2016), 668–670.
42. 42 Kay, MA, Manno, CS, Ragni, MV, Larson, PJ, Couto, LB, McClelland, A, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 24 (2000), 257–261.
43. 43 Manno, CS, Chew, AJ, Hutchison, S, Larson, PJ, Herzog, RW, Arruda, VR, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101 (2003), 2963–2972.
44. 44 Manno, CS, Pierce, GF, Arruda, VR, Glader, B, Ragni, M, Rasko, JJ, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12 (2006), 342–347.
45. 45 Mingozzi, F, Maus, MV, Hui, DJ, Sabatino, DE, Murphy, SL, Rasko, JE, et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 13 (2007), 419–422.
46. 46 Hui, DJ, Podsakoff, GM, Pein, GC, Ivanciu, L, Camire, RM, Ertl, H, et al., High Etiena Basner-Tschakarjan, AAV capsid CD8+ T cell epitopes are highly conserved across AAV serotypes. Mol Ther Methods Clin Dev, 2, 2015, 15029.
47. 47 Nathwani, AC, Gray, JT, McIntosh, J, Ng, CY, Zhou, J, Spence, Y, et al. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood 109 (2007), 1414–1421.
48. 48 Nathwani, AC, Gray, JT, Ng, CY, Zhou, J, Spence, Y, Waddington, SN, et al. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 107 (2006), 2653–2661.
49. 49 Nathwani, AC, Rosales, C, McIntosh, J, Rastegarlari, G, Nathwani, D, Raj, D, et al. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther 19 (2011), 876–885.
50. 50 Nathwani, AC, Reiss, UM, Tuddenham, EG, Rosales, C, Chowdary, P, McIntosh, J, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 371 (2014), 1994–2004.
51. 51 Rogers, GL, Herzog, RW, Gene therapy for hemophilia. Front Biosci (Landmark Ed) 20 (2015), 556–603.
52. 52 Nathwani, AC, Tuddenham, EG, Rangarajan, S, Rosales, C, McIntosh, J, Linch, DC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365 (2011), 2357–2365.
53. 53 VandenDriessche, T, Chuah, MK, Moving forward toward a cure for hemophilia B. Mol Ther 23 (2015), 809–811.
54. 54 Brunetti-Pierri, N, Grove, NC, Zuo, Y, Edwards, R, Palmer, D, Cerullo, V, et al. Bioengineered factor IX molecules with increased catalytic activity improve the therapeutic index of gene therapy vectors for hemophilia B. Hum Gene Ther 20 (2009), 479–485.
55. 55 Cantore, A, Nair, N, Della Valle, P, Di Matteo, M, Màtrai, J, Sanvito, F, et al. Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice. Blood 120 (2012), 4517–4520.
56. 56 Finn, JD, Nichols, TC, Svoronos, N, Merricks, EP, Bellenger, DA, Zhou, S, et al. The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. Blood 120 (2012), 4521–4523.
57. 57 Schuettrumpf, J, Herzog, RW, Schlachterman, A, Kaufhold, A, Stafford, DW, Arruda, VR, Factor IX variants improve gene therapy efficacy for hemophilia B. Blood 105 (2005), 2316–2323.
58. 58 Suwanmanee, T, Hu, G, Gui, T, Bartholomae, CC, Kutschera, I, von Kalle, C, et al. Integration-deficient lentiviral vectors expressing codon-optimized R338L human FIX restore normal hemostasis in Hemophilia B mice. Mol Ther 22 (2014), 567–574.
59. 59 Monahan, PE, Sun, J, Gui, T, Hu, G, Hannah, WB, Wichlan, DG, et al. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial. Hum Gene Ther 26 (2015), 69–81.
60. 60 Monahan, P, Powell, JS, Konkle, BA, Josephson, NC, Escobar, M, McPhee, SJ, et al. Update on a phase 1/2 open-label trial of BAX335, an adeno-associated virus 8 (AAV8) vector-based gene therapy program for hemophilia B. J Thromb Haemost, 13, 2015, 87, 13 87.
61. 61 Herzog, RW, Hemophilia gene therapy: caught between a cure and an immune response. Mol Ther 23 (2015), 1411–1412.
62. 62 Marsic, D, Govindasamy, L, Currlin, S, Markusic, DM, Tseng, YS, Herzog, RW, et al. Vector design Tour de Force: integrating combinatorial and rational approaches to derive novel adeno-associated virus variants. Mol Ther 22 (2014), 1900–1909.
63. 63 Bissig-Choisat, B, Wang, L, Legras, X, Saha, PK, Chen, L, Bell, P, et al. Development and rescue of human familial hypercholesterolaemia in a xenograft mouse model. Nat Commun, 6, 2015, 7339.
64. 64 Lisowski, L, Dane, AP, Chu, K, Zhang, Y, Cunningham, SC, Wilson, EM, et al. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature 506 (2014), 382–386.
65. 65 Schaffer, DV, AAV shuffles to the liver: commentary on Lisowski. Mol Ther Methods Clin Dev, 1, 2014, 14006.
66. 66 Kotterman, MA, Schaffer, DV, Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet 15 (2014), 445–451.
67. 67 Mingozzi, F, Anguela, XM, Pavani, G, Chen, Y, Davidson, RJ, Hui, DJ, et al. Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med, 5, 2013, 194ra92.
68. 68 Hoffman, BE, Herzog, RW, Covert warfare against the immune system: decoy capsids, stealth genomes, and suppressors. Mol Ther 21 (2013), 1648–1650.
69. 69 Martino, AT, Basner-Tschakarjan, E, Markusic, DM, Finn, JD, Hinderer, C, Zhou, S, et al. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121 (2013), 2224–2233.
70. 70 Corti, M, Elder, M, Falk, D, Lawson, L, Smith, B, Nayak, S, et al. B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study. Mol Ther Methods Clin Dev, 1, 2014, 14033.
71. 71 Sarkar, D, Biswas, M, Liao, G, Seay, HR, Perrin, GQ, Markusic, DM, et al. Ex vivo expanded autologous polyclonal regulatory T cells suppress inhibitor formation in hemophilia. Mol Ther Methods Clin Dev, 1, 2014, 14030.
72. 72 Sack, BK, Herzog, RW, Terhorst, C, Markusic, DM, Development of gene transfer for induction of antigen-specific tolerance. Mol Ther Methods Clin Dev, 1, 2014, 14013.
73. 73 Markusic, DM, Hoffman, BE, Perrin, GQ, Nayak, S, Wang, X, LoDuca, PA, et al. Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies. EMBO Mol Med 5 (2013), 1698–1709.
74. 74 Crudele, JM, Finn, JD, Siner, JI, Martin, NB, Niemeyer, GP, Zhou, S, et al. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. Blood 125 (2015), 1553–1561.
75. 75 Finn, JD, Ozelo, MC, Sabatino, DE, Franck, HW, Merricks, EP, Crudele, JM, et al. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood 116 (2010), 5842–5848.
76. 76 Cartier, N, Hacein-Bey-Abina, S, Bartholomae, CC, Veres, G, Schmidt, M, Kutschera, I, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326 (2009), 818–823.
77. 77 Cartier, N, Hacein-Bey-Abina, S, Bartholomae, CC, Bougnères, P, Schmidt, M, Kalle, CV, et al. Lentiviral hematopoietic cell gene therapy for X-linked adrenoleukodystrophy. Methods Enzymol 507 (2012), 187–198.
78. 78 Hwu, WL, Muramatsu, S, Tseng, SH, Tzen, KY, Lee, NC, Chien, YH, et al. Gene therapy for aromatic L-amino acid decarboxylase deficiency. Sci Transl Med, 4, 2012, 134ra61.
79. 79 Lee, NC, Muramatsu, S, Chien, YH, Liu, WS, Wang, WH, Cheng, CH, et al. Benefits of neuronal preferential systemic gene therapy for neurotransmitter deficiency. Mol Ther 23 (2015), 1572–1581.
80. 80 Mittermeyer, G, Christine, CW, Rosenbluth, KH, Baker, SL, Starr, P, Larson, P, et al. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum Gene Ther 23 (2012), 377–381.
81. 81 Leone, P, Shera, D, McPhee, SW, Francis, JS, Kolodny, EH, Bilaniuk, LT, et al. Long-term follow-up after gene therapy for canavan disease. Sci Transl Med, 4, 2012, 165ra163.
82. 82 Samaranch, L, Salegio, EA, San Sebastian, W, Kells, AP, Bringas, JR, Forsayeth, J, et al. Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum Gene Ther 24 (2013), 526–532.
83. 83 Choudhury, SR, Hudry, E, Maguire, CA, Sena-Esteves, M, Breakefield, XO, Grandi, P, Viral vectors for therapy of neurologic diseases. Neuropharmacology, 2016 (epub ahead of print).
84. 84 Bainbridge, JW, Smith, AJ, Barker, SS, Robbie, S, Henderson, R, Balaggan, K, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358 (2008), 2231–2239.
85. 85 Cideciyan, AV, Hauswirth, WW, Aleman, TS, Kaushal, S, Schwartz, SB, Boye, SL, et al. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther 20 (2009), 999–1004.
86. 86 Maguire, AM, Simonelli, F, Pierce, EA, Pugh, EN Jr, Mingozzi, F, Bennicelli, J, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358 (2008), 2240–2248.
87. 87 Boye, SE, Boye, SL, Lewin, AS, Hauswirth, WW, A comprehensive review of retinal gene therapy. Mol Ther 21 (2013), 509–519.
88. 88 Cideciyan, AV, Aleman, TS, Boye, SL, Schwartz, SB, Kaushal, S, Roman, AJ, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci USA 105 (2008), 15112–15117.
89. 89 Hauswirth, WW, Aleman, TS, Kaushal, S, Cideciyan, AV, Schwartz, SB, Wang, L, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 19 (2008), 979–990.
90. 90 Jacobson, SG, Cideciyan, AV, Ratnakaram, R, Heon, E, Schwartz, SB, Roman, AJ, et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 130 (2012), 9–24.
91. 91 Simonelli, F, Maguire, AM, Testa, F, Pierce, EA, Mingozzi, F, Bennicelli, JL, et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 18 (2010), 643–650.
92. 92 Testa, F, Maguire, AM, Rossi, S, Pierce, EA, Melillo, P, Marshall, K, et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology 120 (2013), 1283–1291.
93. 93 Maguire, AM, High, KA, Auricchio, A, Wright, JF, Pierce, EA, Testa, F, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 374 (2009), 1597–1605.
94. 94 Schimmer, J, Breazzano, S, Investor Outlook: Significance of the Positive LCA2 Gene Therapy Phase III Results. Hum Gene Ther Clin Dev 26 (2015), 208–210.
95. 95 Jacobson, SG, Cideciyan, AV, Roman, AJ, Sumaroka, A, Schwartz, SB, Heon, E, et al. Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med 372 (2015), 1920–1926.
96. 96 Bainbridge, JW, Mehat, MS, Sundaram, V, Robbie, SJ, Barker, SE, Ripamonti, C, et al. Long-term effect of gene therapy on Leber's congenital amaurosis. N Engl J Med 372 (2015), 1887–1897.
97. 97 Bennett, J, Ashtari, M, Wellman, J, Marshall, KA, Cyckowski, LL, Chung, DC, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med, 4, 2012, 120ra15.
98. 98 Kostic, C, Crippa, SV, Pignat, V, Bemelmans, AP, Samardzija, M, Grimm, C, et al. Gene therapy regenerates protein expression in cone photoreceptors in Rpe65(R91W/R91W) mice. PLoS One, 6, 2011, e16588.
99. 99 Li, X, Li, W, Dai, X, Kong, F, Zheng, Q, Zhou, X, et al. Gene therapy rescues cone structure and function in the 3-month-old rd12 mouse: a model for midcourse RPE65 leber congenital amaurosis. Invest Ophthalmol Vis Sci 52 (2011), 7–15.
100. 100 Mowat, FM, Breuwer, AR, Bartoe, JT, Annear, MJ, Zhang, Z, Smith, AJ, et al. RPE65 gene therapy slows cone loss in Rpe65-deficient dogs. Gene Ther 20 (2013), 545–555.
101. 101 Cideciyan, AV, Jacobson, SG, Beltran, WA, Sumaroka, A, Swider, M, Iwabe, S, et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci USA 110 (2013), E517–E525.
102. 102 Shanab, AY, Mysona, BA, Matragoon, S, El-Remessy, AB, Silencing p75(NTR) prevents proNGF-induced endothelial cell death and development of acellular capillaries in rat retina. Mol Ther Methods Clin Dev, 2, 2015, 15013.
103. 103 MacLaren, RE, Groppe, M, Barnard, AR, Cottriall, CL, Tolmachova, T, Seymour, L, et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase ½ clinical trial. Lancet 383 (2014), 1129–1137.
104. 104 Koilkonda, RD, Yu, H, Chou, TH, Feuer, WJ, Ruggeri, M, Porciatti, V, et al. Safety and effects of the vector for the Leber hereditary optic neuropathy gene therapy clinical trial. JAMA Ophthalmol 132 (2014), 409–420.
105. 105 Gee, AP, Manufacturing genetically modified T cells for clinical trials. Cancer Gene Ther 22 (2015), 67–71.
106. 106 Carpenito, C, Milone, MC, Hassan, R, Simonet, JC, Lakhal, M, Suhoski, MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA 106 (2009), 3360–3365.
107. 107 Choi, BD, Suryadevara, CM, Gedeon, PC, Herndon, JE 2nd, Sanchez-Perez, L, Bigner, DD, et al. Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. J Clin Neurosci 21 (2014), 189–190.
108. 108 Brentjens, RJ, Rivière, I, Park, JH, Davila, ML, Wang, X, Stefanski, J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118 (2011), 4817–4828.
109. 109 Kalos, M, Levine, BL, Porter, DL, Katz, S, Grupp, SA, Bagg, A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med, 3, 2011, 95ra73.
110. 110 Porter, DL, Levine, BL, Kalos, M, Bagg, A, June, CH, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365 (2011), 725–733.
111. 111 Kochenderfer, JN, Dudley, ME, Feldman, SA, Wilson, WH, Spaner, DE, Maric, I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119 (2012), 2709–2720.
112. 112 Kochenderfer, JN, Dudley, ME, Carpenter, RO, Kassim, SH, Rose, JJ, Telford, WG, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122 (2013), 4129–4139.
113. 113 Lee, DW, Kochenderfer, JN, Stetler-Stevenson, M, Cui, YK, Delbrook, C, Feldman, SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385 (2015), 517–528.
114. 114 Brentjens, RJ, Davila, ML, Riviere, I, Park, J, Wang, X, Cowell, LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med, 5, 2013, 177ra38.
115. 115 Davila, ML, Riviere, I, Wang, X, Bartido, S, Park, J, Curran, K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med, 6, 2014, 224ra25.
116. 116 Maude, SL, Frey, N, Shaw, PA, Aplenc, R, Barrett, DM, Bunin, NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371 (2014), 1507–1517.
117. 117 Grupp, SA, Kalos, M, Barrett, D, Aplenc, R, Porter, DL, Rheingold, SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368 (2013), 1509–1518.
118. 118 Blat, D, Zigmond, E, Alteber, Z, Waks, T, Eshhar, Z, Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Mol Ther 22 (2014), 1018–1028.
119. 119 Fransson, M, Piras, E, Burman, J, Nilsson, B, Essand, M, Lu, B, et al. CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery. J Neuroinflammation, 9, 2012, 112.
120. 120 Shimasaki, N, Fujisaki, H, Cho, D, Masselli, M, Lockey, T, Eldridge, P, et al. A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy 14 (2012), 830–840.
121. 121 Kim, YC, Zhang, AH, Su, Y, Rieder, SA, Rossi, RJ, Ettinger, RA, et al. Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses. Blood 125 (2015), 1107–1115.
122. 122 Wang, X, Moghimi, B, Zolotukhin, I, Morel, LM, Cao, O, Herzog, RW, Immune tolerance induction to factor IX through B cell gene transfer: TLR9 signaling delineates between tolerogenic and immunogenic B cells. Mol Ther 22 (2014), 1139–1150.
123. 123 Zhen, A, Kamata, M, Rezek, V, Rick, J, Levin, B, Kasparian, S, et al. HIV-specific immunity derived from chimeric antigen receptor-engineered stem cells. Mol Ther 23 (2015), 1358–1367.
124. 124 Duval, L, Schmidt, H, Kaltoft, K, Fode, K, Jensen, JJ, Sorensen, SM, et al. Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma. Clin Cancer Res 12 (2006), 1229–1236.
125. 125 Johnson, LA, Morgan, RA, Dudley, ME, Cassard, L, Yang, JC, Hughes, MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114 (2009), 535–546.
126. 126 Morgan, RA, Dudley, ME, Wunderlich, JR, Hughes, MS, Yang, JC, Sherry, RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (2006), 126–129.
127. 127 Parkhurst, MR, Yang, JC, Langan, RC, Dudley, ME, Nathan, DA, Feldman, SA, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 19 (2011), 620–626.
128. 128 Pule, MA, Savoldo, B, Myers, GD, Rossig, C, Russell, HV, Dotti, G, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14 (2008), 1264–1270.
129. 129 Robbins, PF, Morgan, RA, Feldman, SA, Yang, JC, Sherry, RM, Dudley, ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29 (2011), 917–924.
130. 130 Morgan, RA, Yang, JC, Kitano, M, Dudley, ME, Laurencot, CM, Rosenberg, SA, Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18 (2010), 843–851.
131. 131 Linette, GP, Stadtmauer, EA, Maus, MV, Rapoport, AP, Levine, BL, Emery, L, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122 (2013), 863–871.
132. 132 Morgan, RA, Chinnasamy, N, Abate-Daga, D, Gros, A, Robbins, PF, Zheng, Z, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36 (2013), 133–151.
133. 133 Rapoport, AP, Stadtmauer, EA, Binder-Scholl, GK, Goloubeva, O, Vogl, DT, Lacey, SF, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med 21 (2015), 914–921.
134. 134 Lichty, BD, Breitbach, CJ, Stojdl, DF, Bell, JC, Going viral with cancer immunotherapy. Nat Rev Cancer 14 (2014), 559–567.
135. 135 Tebas, P, Stein, D, Tang, WW, Frank, I, Wang, SQ, Lee, G, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 370 (2014), 901–910.
136. 136 Swiech, L, Heidenreich, M, Banerjee, A, Habib, N, Li, Y, Trombetta, J, et al. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol 33 (2015), 102–106.
137. 137 Yin, H, Xue, W, Chen, S, Bogorad, RL, Benedetti, E, Grompe, M, et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 32 (2014), 551–553.
138. 138 Barzel, A, Paulk, NK, Shi, Y, Huang, Y, Chu, K, Zhang, F, et al. Promoterless gene targeting without nucleases ameliorates haemophilia B in mice. Nature 517 (2015), 360–364.
139. 139 Li, H, Haurigot, V, Doyon, Y, Li, T, Wong, SY, Bhagwat, AS, et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 475 (2011), 217–221.
140. 140 Frederickson, R, Ylä-Herttuala, S, Molecular therapy special issue on gene editing technologies and applications. Mol Ther, 23, 2015, 1279.
141. 141 Wang, J, Exline, CM, DeClercq, JJ, Llewellyn, GN, Hayward, SB, Li, PW, et al. Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat Biotechnol 33 (2015), 1256–1263.
142. 142 Sather, BD, Romano Ibarra, GS, Sommer, K, Curinga, G, Hale, M, Khan, IF, et al. Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci Transl Med, 7, 2015, 307ra156.